Calla M Olson

Introduction: Calla M Olson is an accomplished inventor based in Brookline, MA (US). She has made significant contributions to the field of biochemistry, particularly in the development of innovative compounds for cancer treatment. With a total of six patents to her name, Olson is recognized for her groundbreaking work in targeted protein degradation.

Latest Patents: Among her latest patents is a groundbreaking invention titled "Degraders of WEE1 kinase." This patent discloses bifunctional compounds that target Wee1 tyrosine kinase for degradation. Additionally, she has developed pharmaceutical compositions containing these degraders and methods for using them to treat diseases. Another notable patent focuses on the "Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use." This application provides bifunctional compounds that act as protein degradation inducing moieties for CDK8, which can be utilized in the treatment of disorders modulated by this kinase.

Career Highlights: Calla M Olson is currently affiliated with the Dana-Farber Cancer Institute Inc., where she continues her research and development efforts. Her work has been instrumental in advancing therapeutic strategies for cancer treatment.

Collaborations: Throughout her career, Olson has collaborated with esteemed colleagues, including Nathanael Schiander Gray and Tinghu Zhang.

This text is generated by artificial intelligence and may not be accurate.